BioSpace News Archive

LOVE Pharma (CSE:LUV) (FSE:G1Q0) which on October 11th signed a nonbinding Letter of Intent to acquire 100% of Naltrexone Therapeutics, reports recent developments on Naltrexone’s application for long COVID.

Sensient Technologies Corporation reported consolidated revenue of $361.1 million in this year’s third quarter compared to $344.3 million in last year’s third quarter.

Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced it has filed and mailed a shareholder circular (the “Shareholder Circular”) and related meeting and proxy materials in connection with its upcoming General Meeting of Shareholders (the “General Meeting”) to be held on November 18, 2022 at 2:00 p.m. London time.

Prelude Corporation announced today that its prospective data of 926 patients demonstrating the clinical utility of DCISionRT and its Residual Risk Subtype (RRt) was selected for a scientific session oral presentation at the 64th Annual American Society for Radiation Oncology (ASTRO) Meeting, to be held on October 23 – 26, 2022 at the Henry B. Gonzalez Convention Center in San Antonio, TX.

Acorda Therapeutics, Inc. (Nasdaq: ACOR) will hold a virtual, video Q&A with its CEO, Ron Cohen, M.D., on Friday, October 28 at 1:00pm ET, 10:00am PT.

Sientra, Inc. today announced the pricing of its previously announced underwritten public offering of 34,782,600 shares of its common stock (or common stock equivalents) and accompanying warrants to purchase up to an aggregate of 34,782,600 shares of common stock.

RaySearch Laboratories AB (publ) will be showcasing the latest oncology software innovations at ASTRO 2022, to be held in San Antonio, October 23-25.

ARS Pharmaceuticals Announces FDA Acceptance of NDA for neffy ® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) Including Anaphylaxis.

Eyenovia, Inc. announced the company will present at the 2022 American Academy of Optometry’s Annual Meeting, which is taking place from October 26-29, 2022, at the at the San Diego Convention Center.

Matinas BioPharma Holdings, Inc. today announced positive interim data from Cohort 4, the fourth and final cohort of the Phase 2 EnACT trial evaluating MAT2203, an oral LNC formulation of amphotericin B, for the treatment of cryptococcal meningitis.